Application 220449
- Type
- NDA
- Sponsor
- BOEHRINGER INGELHEIM
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | JASCAYD | NERANDOMILAST | TABLET;ORAL | 9MG | Yes | No |
| 002 | JASCAYD | NERANDOMILAST | TABLET;ORAL | 18MG | Yes | Yes |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| JASCAYD | NERANDOMILAST | Boehringer Ingelheim Pharmaceuticals, Inc. | fa1b14c6-957f-d326-5099-911bfe33e391 | 2026-08-14 | Adverse reactions | JASCAYD NERANDOMILAST |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.